Coartem Baby – First Malaria Drug for Infants

Source: TOI

Context: Switzerland has approved Coartem Baby, the first-ever malaria treatment for newborns and infants, developed by Novartis. Eight African nations are expected to follow with fast-track approvals.

About Coartem Baby – First Malaria Drug for Infants:

• What it is?

• A new pediatric formulation of artemether-lumefantrine, named Coartem Baby, specifically designed for infants weighing 2–5 kg (newborns to under 6 months).

• Developed by:

• Novartis, in collaboration with Medicines for Malaria Venture (MMV) and other global health partners.

• Objective:

• To close the treatment gap for malaria in the most vulnerable age group — newborns and very young infants, previously excluded from clinical trials and vaccination coverage.

• Key Features:

• Dissolves easily, even in breast milk. Cherry-flavoured to ensure better infant compliance. Clinically tested dose ratio for infants with immature liver function. Approved under Swiss medic’s Marketing Authorisation for Global Health Products pathway. Will be offered largely not-for-profit in malaria-endemic countries.

• Dissolves easily, even in breast milk.

• Cherry-flavoured to ensure better infant compliance.

• Clinically tested dose ratio for infants with immature liver function.

• Approved under Swiss medic’s Marketing Authorisation for Global Health Products pathway.

• Will be offered largely not-for-profit in malaria-endemic countries.

• Significance:

• Fills a critical public health gap: no malaria drugs were previously approved for babies under 4.5 kg. Improves safety by eliminating off-label dosing from older children’s formulations. Expected to be approved soon in 8 African nations: Kenya, Tanzania, Uganda, Nigeria, Malawi, Mozambique, Burkina Faso, and Ivory Coast. Addresses malaria risk in ~30 million newborns born annually in Africa’s endemic zones.

• Fills a critical public health gap: no malaria drugs were previously approved for babies under 4.5 kg.

• Improves safety by eliminating off-label dosing from older children’s formulations.

• Expected to be approved soon in 8 African nations: Kenya, Tanzania, Uganda, Nigeria, Malawi, Mozambique, Burkina Faso, and Ivory Coast.

• Addresses malaria risk in ~30 million newborns born annually in Africa’s endemic zones.